Mainstay Medical has said it will need to raise about $50 million (€45 million) if it secures approval from drug regulators to launch its chronic back pain treatment in America
Dublin stock market-listed Mainstay has submitted its treatment for pre-market approval by the US Food & Drug Administration (FDA) and is hopeful of securing the green light late next year.
Jason Hannon, Mainstay’s chief executive, said data submitted to the FDA based on patients using its...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team